SynthesisFrontiers in endocrinology2025
Metabolic syndrome components individually worsen the outcome of acute pancreatitis: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Persistent pancreatic enzyme elevation is correlated with superinfection in acute pancreatitis with fluid collections: a prospective, multicentre cohort analysis.Frontiers in cellular and infection microbiology · 2026Article
- Cross-sectional analysis of the association between physical activity and metabolic syndrome in the elderly.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The obesity epidemic has led to a rise in related health conditions, with metabolic syndrome (MS) affecting 25% of Western populations. In severe acute pancreatitis (AP), mortality can reach 50%. Previous studies have linked MS elements to increased complications and mortality in AP. This meta-analysis aims to identify potential risk factors and their synergistic effects on AP outcomes. Methods: We systematically searched PubMed, Embase, and the Cochrane Library up to November 1, 2023, and included studies based on predefined criteria. We examined the impact of MS and its factors (obesity, hypertension, diabetes mellitus, and hypertriglyceridemia) on AP outcomes, calculating pooled odds ratios (OR) with 95% confidence intervals (CIs). The protocol was registered in PROSPERO under number CRD42023471092. Results: Out of 15,904 records, 89 studies were analyzed. Overweight and obesity were significant risk factors for complications (local OR: 2.677, 95%CI: 1.421-5.044; systemic OR: 2.404, 95%CI: 1.481-3.901) and severe AP (BMI≥30 kg/m Conclusion: Individual components of MS are risk factors for complications, severity, and mortality in AP. Lifestyle counseling, education, and treatment of patients with obesity is crucial. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CD42023471092.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.